Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drug resistant bacterial infections, today announced positive top-line results from the Phase 2 study of its lead antibiotic candidate, an extended spectrum β-lactamase inhibitor known as AAI101.
Allecra Therapeutics Announces Positive Top-Line Results from Phase 2 CACTUS Study of its Lead Candidate, AAI101, in Combination with Cefepime to Treat Complicated Urinary Tract Infections (cUTI)
ViraTherapeutics starts second oncolytic virus development program with Boehringer Ingelheim
ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic virus therapies, today announced the expansion of its current collaboration with Boehringer Ingelheim, with a second oncolytic virus program. The new development program is an oncolytic virus, stemming from ViraTherapeutics’ technology platform. The Vesicular Stomatitis Virus (VSV) will be armed with an additional immunotherapeutic component from Boehringer Ingelheim.
Allecra Therapeutics Announces Fast Track Designation for Lead Antibiotic in Resistant Infections
Allecra Therapeutics, a biopharmaceutical company dedicated to the development of novel antibiotics for the treatment of drugresistant bacterial infections, announces today that the U.S Food and Drug Administration (FDA) has granted Fast Track designation for the company’s lead product candidate AAI101 when given in fixed dose combination with the antibiotic cefepime, a powerful treatment for serious hospital-acquired Infections.